Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Castle Biosciences ( (CSTL) ) has issued an announcement.
Castle Biosciences announced preliminary unaudited results for 2024, expecting total revenue to meet or exceed the top end of the guided range of $320-330 million, marking over 50% growth from 2023. The company delivered 96,071 total test reports in 2024, a 36% increase from the previous year, driven by various tests including DecisionDx®-Melanoma and TissueCypher® Barrett’s Esophagus. Despite the growth, a recent Medicare decision signified non-coverage for the DecisionDx-SCC test, impacting future reimbursement. The results underscore Castle Biosciences’ momentum and commitment to advancing health through patient-centric diagnostics.
More about Castle Biosciences
Castle Biosciences is a leading diagnostics company focused on improving health through innovative tests that guide patient care. Their portfolio includes tests for skin cancers, Barrett’s esophagus, mental health conditions, and uveal melanoma, with ongoing research and development programs targeting diseases with high clinical need.
YTD Price Performance: 7.88%
Average Trading Volume: 393,976
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $847.2M
See more data about CSTL stock on TipRanks’ Stock Analysis page.
